Posts Feed
Comments Feed

Archive for the 'Crohn' Category

For Crohn’s Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse

Administrationof omega-3 fatty acid supplements did not appear to improve the rate ofrelapse in patients with Crohn’s disease, according to a study releasedon April 9, 2008 in JAMA. Crohn’sDisease is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.

More: continued here

No Comments »

Large Multi Center Study Suggests New Genetic Markers For Crohn’s Disease

What is believed to be the largest study of its kind for the genetic roots of inflammatory bowel diseases has suggested new links to Crohn’s Disease as well as further evidence that some people of Jewish descent are more likely to develop it.

More: continued here

No Comments »

CHMP Upholds Negative Opinion For The EU Application For Cimzia(R) In The Treatment Of Crohn’s Disease

UCB announced that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn’s disease, a chronic and debilitating inflammatory disease.

More: continued here

No Comments »

Food For Life Baking Co., Inc. Recalls Spelt Bread , California - Product Contains Undeclared Wheat

Food For Life Baking Company of Corona, California is voluntarily recalling 2,241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat. People who have allergies to wheat or those with Celiac Disease may run the risk of a serious or life threatening allergic reaction if they consume spelt products. The recalled products were sold nationwide through health food distributors and natural food retailers.

More: continued here

No Comments »

CHMP Upholds Negative Opinion For The EU Application For Cimzia® In The Treatment Of Crohn’s Disease

UCB announced today that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn’s disease, a chronic and debilitating inflammatory disease.

More: continued here

No Comments »

Early Data On Cimzia® Shows Promise In Crohn’s Patients Without Infliximab

Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn’s and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia® (certolizumab pegol) is effective in Crohn’s patientsshowing intolerance or no response to infliximab. Crohn’sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.

More: continued here

No Comments »

Hope For Crohn’s Patients With Fistulas Found In HUMIRA/Adalimumab

At the recent European Crohn’s and Colitis Organization (ECCO) annualmeeting in Lyon, France, Abbott Laboratories announced that HUMIRA(Adalimumab) is successful in the treatment of fistulas in susceptibleCrohn’s patients. Crohn’sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract.

More: continued here

No Comments »

Caspase-12: MUHC Researcher Finds New Defense Mechanism Against Intestinal Inflammation

The body’s first line of defence against pathogenic bacteria that we ingest may not be the immune system but rather the cells that line the intestine. This surprising conclusion is just one facet of a study by Dr. Maya Saleh, a researcher at the Research institute of the McGill University Health Centre, published in the journal Cell Host & Microbe on March 12.

More: continued here

No Comments »

New Treatment Strategy For Crohn’s Disease Shows Promise

When treating patients with Crohn’s disease, early use of an intensivecombined immunosuppression (CI) in combination withconventional management is more effective than the current standard,treatment with corticosteroids. These outcomes were reported in anArticle in the February 23, 2008 issue of The Lancet.

More: continued here

No Comments »

Inflammatory Bowel Disease May Mimic Gynecological Disorders In Its Clinical Presentation

Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis. When the disease involves the small bowel, it usually has a benign course, but in rare circumstances, it may present as abdominal emergency. Invasive bowel endometriosis can present as bowel obstruction.

More: continued here

No Comments »

« Prev - Next »